Dr. Janet Woodcock and other top FDA officials left the "door open" for accelerated approval of Sarepta's (SRPT) drug, eteplirsen at Monday's advisory panel, TheStreet's Adam Feuerstein writes. "Woodcock's actions both during and after the eteplirsen advisory panel suggest another surprising twist in the Sarepta story could play out," he contends.

Shares of Sarepta are up 15% to $13.23 following Feuerstein's article. 

Reference link